Project Grant K23AI202908
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $199K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55415, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $2 million on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of cross-species virus infections and predict spillover events into human populations. The research exploits a novel resource called the "Fibroblast Zoo," a collection of primary dermal fibroblasts from 89 mammalian species, to determine host factors...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $700,997 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune homeostasis during Borrelia burgdorferi infection. The research defines the impact of BB infection-induced changes in gastrointestinal barrier function and microbiota on immune system health. The project tests the hypothesis that BB infection-induced gut barrier dysfunction,...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $749,736 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the biology of picobirnaviruses. The project seeks to establish culture systems and identify the host organisms of picobirnaviruses (PBVs), small double-stranded, bisegmented RNA viruses detected at high prevalence in the human enteric tract and linked to type 1 diabetes and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $417,845 to the University of Nebraska Medical Center under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period from August 1, 2025, through July 31, 2027. The award supports the development and adaptation of an innovative in vitro organotypic human skin model designed to enable tick feeding and study the transmission and colonization of Borrelia...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $159,140 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular epidemiology research on New Delhi metallo-B-lactamase-producing Enterobacterales (NDM-E) infections. The research integrates genotype, phenotype, and patient-level outcomes to develop allele-specific therapeutic guidance for NDM-E treatment. Aim 1 defines the genetic epidemiology of...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $423,500 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will generate and validate a series of TAM receptor tyrosine kinase (Tyro3, Axl, and Merkt) mutant mice designed to disentangle specific effector functions—phagocytosis of dead cells and anti-inflammatory signaling—rather than produce complete knockouts. By substituting...
- The National Institute of Allergy and Infectious Diseases awarded the President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) $228,000 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI196865). The award funds therapeutic repurposing research to identify new treatment options for human babesiosis, a tick-borne parasitic disease transmitted alongside Lyme disease that has more than doubled in incidence over...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts Institute of Technology $185,472 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on molecular host determinants of spotted fever group rickettsial infection. The funded research addresses host-pathogen interactions in Rickettsia species, obligate intracellular bacterial pathogens that cause tickborne vascular endothelial diseases with rising global...
- The National Institute of Allergy and Infectious Diseases awarded The Rockefeller University $195,523 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into host and viral determinants of hepatitis B virus transcription. The research examines mechanisms by which episomal DNA transcription is silenced and promoted through the lens of hepatitis B virus, with focus on how the viral regulatory X protein (HBX) promotes transcription and other...